Impact of SARS-CoV-2 infection on graft composition and early transplant outcomes following allogeneic hematopoietic stem cell transplantation

• Published in: Zhōnghuá xuèyèxué zázhì 2023-11, Vol.44 (11), p.890-899
• Main Authors: Lin, F, Sun, H, Chen, Y, Zhang, Y Y, Liu, J, He, Y, Zheng, F M, Xu, Z L, Wang, F R, Kong, J, Wang, Z D, Wan, Y Y, Mo, X D, Wang, Y, Cheng, Y F, Zhang, X H, Huang, X J, Xu, L P
• Format: Article
• Language: Chinese
• Subjects: COVID-19; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; SARS-CoV-2; Tissue Donors
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2023.11.002

To assess the feasibility of using donors with novel coronavirus disease 2019 (COVID-19) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) when there are no other available donors and allo-HSCT cannot be delayed or discontinued. Seventy-one patients with malignant hematological diseases undergoing allo-HSCT between December 8, 2022, and January 10, 2023, were included. Of these, 16 received grafts from donors with mild COVID-19 (D-COVID(+) group) and 55 received grafts from donors without COVID-19 (D-COVID(-) group). The graft compositions were compared between the two groups. Engraftment, acute graft-versus-host disease (aGVHD), overall survival (OS), and relapse were also evaluated. There were no serious side effects or adverse events in the D-COVID(+) group. The mononuclear cell dose and CD34(+) cell dose were comparable between the two groups, and no additional apheresis was required. There were no significant differences in the lymphocyte, monocyte, and T-cell subset doses between the tw